Exploring Improving Penetration of Anti-Cancer Drugs Into TME & Designing Bispecific ADCs
9:30 am - Tuesday 9th June 2026
- Exploring PMC-403, a novel TIE2 trans binding vessel normalizer in TME
- Introducing PMC-005 (EGFRviii) and PAb-100 (MUC1) and exploring bispecific ADC
- Discussing a hypothesis of PMC-403 and Bispecific ADC targeting EGFRviii and MUC1
